HER2+ Gastric Cancer Pipeline Appears Promising With 20+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
Explore our latest breakthroughs in HER2 Positive Gastric Cancer Research. Learn more about our innovative pipeline today! @ HER2 Positive Gastric Cancer Pipeline Outlook
Key Takeaways from the HER2 Positive Gastric Cancer Pipeline Report
In July 2025, AstraZeneca announced a study is to assess the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.
In July 2025, Daiichi Sankyo conducted a clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy and safety of T-DXd plus a fluoropyrimidine versus SoC chemotherapy plus trastuzumab in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS
DelveInsight's HER2 Positive Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2 Positive Gastric Cancer treatment.
The leading HER2 Positive Gastric Cancer Companies such as Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
Promising HER2 Positive Gastric Cancer Therapies such as YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.
Stay informed about the cutting-edge advancements in HER2 Positive Gastric Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ HER2 Positive Gastric Cancer Clinical Trials Assessment
HER2 Positive Gastric Cancer Emerging Drugs
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
SHR-A1811 is a novel anti-HER2 antibody-drug conjugate (ADC) that features an optimized molecular design to enhance plasma stability and bystander effect. Hengrui Pharma is currently conducting more than 10 clinical studies of SHR-A1811 from phase 1 to phase 3 to evaluate its safety and efficacy as single agent or combination therapy in a wide variety of cancer indications. Currently, the drug is in Phase III stage of its development for the treatment of HER2-positive Gastric Cancer.
Cinrebafusp alfa: Pieris Pharmaceuticals
Cinrebafusp alfa (PRS-343) is a 4-1BB/HER2 fusion protein comprising 4-1BB-targeting Anticalin proteins and a HER2-targeting antibody. The drug candidate is currently in phase 2 development for the treatment of HER2-expressing solid tumors. In phase 1 studies, cinrebafusp alfa has shown an acceptable safety profile at all doses tested with no dose-limiting toxicities. The bispecific also showed a dose response and a 4-1BB-driven mechanism of action based on clinical benefit and pharmacodynamic correlates. Currently, the drug is in Phase II stage of its development for the treatment of HER2-positive Gastric Cancer.
BI-1607 is an FcγRIIB-blocking antibody that differs from BI-1206 (BioInvent's clinical-stage FcγRIIB antibody) in that it has been engineered for reduced Fc-binding to FcγRs. Preclinical proof-of-concept data indicate that combined treatment with BI-1607 may both enhance efficacy of current anti-HER2 regimens and increase response rates in patients no longer responding to anti-HER2-directed therapies such as trastuzumab. Currently, the drug is in Phase I/II stage of its development for the treatment of HER2-positive Gastric Cancer.
The HER2 Positive Gastric Cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Positive Gastric Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Positive Gastric Cancer Treatment.
HER2 Positive Gastric Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
HER2 Positive Gastric Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Positive Gastric Cancer market.
Learn more about HER2 Positive Gastric Cancer Drugs opportunities in our groundbreaking HER2 Positive Gastric Cancer Research and development projects @ HER2 Positive Gastric Cancer Unmet Needs
HER2 Positive Gastric Cancer Companies
Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
HER2 Positive Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Oral
Intravenous
Subcutaneous
Parenteral
Topical
HER2 Positive Gastric Cancer Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Discover the latest advancements in HER2 Positive Gastric Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ HER2 Positive Gastric Cancer Market Drivers and Barriers, and Future Perspectives
HER2 Positive Gastric Cancer Companies and Therapies
BDC-1001: Bolt Therapeutics Inc.
KN026: Shanghai JMT-Bio Inc.
YH32367: Yuhan Corporation
Margetuximab: MacroGenics
Zanidatamab: Jazz Pharmaceuticals
Scope of the HER2 Positive Gastric Cancer Pipeline Report
Coverage- Global
HER2 Positive Gastric Cancer Companies- Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
HER2 Positive Gastric Cancer Therapies- YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.
HER2 Positive Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
HER2 Positive Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of HER2 Positive Gastric Cancer Pipeline on our website @ HER2 Positive Gastric Cancer Drugs and Companies
Table of Content
Introduction
Executive Summary
HER2-positive Gastric Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
HER2-positive Gastric Cancer– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Cinrebafusp alfa: Pieris Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
BI-1607: BioInvent International
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
HER2-positive Gastric Cancer Key Companies
HER2-positive Gastric Cancer Key Products
HER2-positive Gastric Cancer- Unmet Needs
HER2-positive Gastric Cancer- Market Drivers and Barriers
HER2-positive Gastric Cancer- Future Perspectives and Conclusion
HER2-positive Gastric Cancer Analyst Views
HER2-positive Gastric Cancer Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
NiCE and RingCentral Extend Partnership to Accelerate AI-Driven Customer and Employee Experiences
NiCE (Nasdaq: NICE) today announced a renewed collaboration with RingCentral, Inc. (NYSE: RNG), a global leader in AI-powered business communications, through a multi-year extension of their long-term agreement to market and sell RingCentral Contact Center ™, a proven, global solution for enterprise-grade customer engagement, powered by NiCE CXone Mpower. The extension builds upon the partnership NiCE and RingCentral have cultivated since 2015, and re-energizes the partnership in go-to-market, sales, onboarding, and post sales engagement. The extended partnership helps businesses transform and deliver AI-powered customer experiences. RingCentral is a recognized leader in cloud business communications, and named a Leader in the Gartner® Magic Quadrant for Unified Communications as a Service (UCaaS) report for 10 consecutive years. In addition, NiCE is a recognized industry leader in cloud contact center and CX, and named a Leader* in the Gartner® Magic Quadrant TM for Contact Center as a Service (CCaaS)** report for 10 consecutive years. Together, the two companies have a successful track record of offering a deeply integrated UCaaS and CCaaS solution. 'We're thrilled to extend our partnership with NiCE and double down on continuing to offer NiCE's renowned industry-leading CX platform powered by AI to RingCentral's enterprise customers,' said Vlad Shmunis, Founder, Chairman and CEO of RingCentral. 'Our customers greatly benefit from the integration of two recognized industry leaders that no other vendors are able to deliver. This partnership extension marks an important next chapter, and we look forward to working with the NiCE team offering our AI-powered integrated solution streamlining customer interactions and boosting overall efficiency.' 'RingCentral is a recognized leader in cloud business communications, and we're excited to work together to take our partnership with RingCentral to the next level – one defined by the seamless convergence of AI powered customer and employee experiences,' said Scott Russell, CEO of NiCE. 'The path ahead is about working together collaboratively to unlock more opportunities — and meet businesses wherever they are in their AI journey to modernize how they connect, collaborate, and serve their customers.' A key component of the extended partnership will be focused on re-energizing the channel partner ecosystem, where RingCentral Contact Center powered by NiCE CXone Mpower has long been recognized and sold successfully as a leading integrated solution. According to Joe Rittenhouse, Co-CEO of Converged Technology Professionals, Inc., 'The NiCE and RingCentral partnership extension is a significant win-win. We're great supporters of this partnership and have successfully sold and deployed many large enterprise deals based on their integrated UCaaS and CCaaS solutions. We look forward to the next steps and their focus on working together with us to make our clients super successful.' 'The past 10 years of the NiCE and RingCentral partnership has been an interesting journey, and one that has seen notable success. Few other vendors in the UCaaS and CCaaS market have been able to integrate that deeply and reach a level of success seen by this partnership, so I look forward to seeing what's next and how NiCE and RingCentral will help customers in their AI powered EX and CX journeys,' said Zeus Kerravala, Founder and Principal Analyst of ZK Research. For more information on RingCentral Contact Center, please visit: *NiCE recognized as inContact in 2015 and 2016, recognized as NiCE inContact in 2017, 2018, 2019 and 2020 and recognized as NiCE CXone in 2021. **Recognized in the Magic Quadrant for Contact Center as a Service, North America from 2015 to 2019. Gartner, Magic Quadrant for Contact Center as a Service, By Drew Kraus, Pri Rathnayake, Megan Fernandez, Pankil Sheth, Jason Bridge, 28 October 2024. Gartner, Critical Capabilities for Unified Communications as a Service, By Rafael Benitez, Megan Fernandez, Christopher Trueman, Pankil Sheth, 14 October 2024. Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's Research & Advisory organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved. About RingCentral RingCentral is a global leader in AI-powered business communications, contact center, conversational intelligence, video and hybrid event solutions. RingCentral empowers businesses with conversation intelligence and unlocks rich customer and employee interactions to provide insights and improved business outcomes. With decades of expertise in reliable and secure cloud communications, RingCentral has earned the trust of hundreds of thousands of customers and millions of users worldwide. Visit to learn more. © 2025 RingCentral, Inc. All rights reserved. RingCentral, RingCentral Contact Center, and the RingCentral logo are trademarks of RingCentral, Inc. About NiCE NiCE (NASDAQ: NICE) is transforming the world with AI that puts people first. Our purpose-built AI-powered platforms automate engagements into proactive, safe, intelligent actions, empowering individuals and organizations to innovate and act, from interaction to resolution. Trusted by organizations throughout 150+ countries worldwide, NiCE's platforms are widely adopted across industries connecting people, systems, and workflows to work smarter at scale, elevating performance across the organization, delivering proven measurable outcomes. Trademark Note: NiCE and the NiCE logo are trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE's marks, please see: Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Russell, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the 'Company'). In some cases, such forward-looking statements can be identified by terms such as 'believe,' 'expect,' 'seek,' 'may,' 'will,' 'intend,' 'should,' 'project,' 'anticipate,' 'plan,' 'estimate,' or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in general economic and business conditions; competition; successful execution of the Company's growth strategy; success and growth of the Company's cloud Software-as-a-Service business; rapid changes in technology and market requirements; the implementation of AI capabilities in certain products and services, decline in demand for the Company's products; inability to timely develop and introduce new technologies, products and applications; difficulties in making additional acquisitions or difficulties or effectively integrating acquired operations; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company's dependency on third-party cloud computing platform providers, hosting facilities and service partners; cyber security attacks or other security incidents; privacy concerns; changes in currency exchange rates and interest rates, the effects of additional tax liabilities resulting from our global operations, the effect of unexpected events or geo-political conditions, including those arising from political instability or armed conflict that may disrupt our business and the global economy; our ability to recruit and retain qualified personnel; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the 'SEC'). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company's reports filed from time to time with the SEC, including the Company's Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.
Globe and Mail
an hour ago
- Globe and Mail
Coursera to Participate in the KeyBanc Capital Markets' Technology Leadership Forum
Coursera, Inc. (NYSE: COUR), a leading global online learning platform, announces that Ken Hahn, Coursera's chief financial officer, is scheduled to participate in a fireside chat at the KeyBanc Capital Markets' Technology Leadership Forum on Monday, August 11, 2025 at 3:00 p.m. MT / 5:00 p.m. ET. A live webcast and archived replay of the virtual fireside chat will be available on Coursera's Investor Relations website at Disclosure Information In compliance with disclosure obligations under Regulation FD, Coursera announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission ('SEC'), press releases, company blog posts, public conference calls, and webcasts, as well as via Coursera's investor relations website. About Coursera Coursera was launched in 2012 by Andrew Ng and Daphne Koller with a mission to provide universal access to world-class learning. It is now one of the largest online learning platforms in the world, with 183 million registered learners as of June 30, 2025. Coursera partners with over 350 leading university and industry partners to offer a broad catalog of content and credentials, including courses, Specializations, Professional Certificates, and degrees. Coursera's platform innovations enable instructors to deliver scalable, personalized, and verified learning experiences to their learners. Institutions worldwide rely on Coursera to upskill and reskill their employees, citizens, and students in high-demand fields such as GenAI, data science, technology, and business. Coursera is a Delaware public benefit corporation and a B Corp.
Globe and Mail
an hour ago
- Globe and Mail
C.H. Robinson to Participate in Deutsche Bank 2025 Transportation Conference
C.H. Robinson (NASDAQ: CHRW) announced that the company will participate in a fireside chat at the Deutsche Bank 2025 Transportation Conference on Tuesday, August 12, 2025, at 1:00 p.m. Eastern Time. A live webcast of the fireside chat discussion will be available at A replay of the webcast will be available within 24 hours following the live event. About C.H. Robinson C.H. Robinson delivers logistics like no one else™. Companies around the world look to us to reimagine supply chains, advance freight technology, and solve logistics challenges—from the simple to the most complex. 83,000 customers and 450,000 contract carriers in our network trust us to manage 37 million shipments and $23 billion in freight annually. Through our unmatched expertise, unrivaled scale, and tailored solutions, we ensure the seamless delivery of goods across industries and continents via truckload, less-than-truckload, ocean, air, and beyond. As a responsible global citizen, we make supply chains more sustainable and proudly contribute millions to the causes that matter most to our employees. For more information, visit us at (Nasdaq: CHRW).
